Initiating Free Research Reports on Canopy Growth and Three Other Drug Makers Equities

Stock Research Monitor: RDY, MEIP, and SGYP

LONDON, UK / ACCESSWIRE / June 28, 2018 / If you want a free Stock Review on CGC sign up now at www.wallstequities.com/registration. This morning, WallStEquities.com tracks the performance of select Drug Manufacturers stocks, particularly: Canopy Growth Corp. (NYSE: CGC), Dr. Reddy’s Laboratories Ltd (NYSE: RDY), MEI Pharma Inc. (NASDAQ: MEIP), and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Companies in the pharmaceutical manufacturing industry manufacture and process pharmaceutical products. These manufacturers compete to discover and commercialize ever-more effective medicines.All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Canopy Growth

Smiths Falls, Canada headquartered Canopy Growth Corp.’s stock finished Wednesday’s session 10.79% lower at $27.61. A total volume of 6.71 million shares was traded, which was above their three months average volume of 1.83 million shares. The Company’s shares have advanced 10.48% over the previous three months and 354.93% over the past year. The stock is trading above its 50-day and 200-day moving averages by 1.75% and 33.51%, respectively. Furthermore, shares of Canopy Growth, which through its subsidiaries, produces and sells medical marijuana in Canada, have a Relative Strength Index (RSI) of 43.17.

On June 25th, 2018, Canopy Growth announced the addition of well-respected cannabis industry leaders, Kirk Tousaw and Mat Beren, to its West Coast bench. Tousaw and Beren will provide consulting services and collaborate with the Company as it continues to enhance quality while also supporting advocacy and community engagement. Get the full research report on CGC for free by clicking below at:

www.wallstequities.com/registration/?symbol=CGC

Dr. Reddy’s Laboratories

Shares in Hyderabad, India headquartered Dr. Reddy’s Laboratories Ltd ended at $32.43, down slightly by 0.80% from the last trading session. The stock recorded a trading volume of 433,379 shares. The Company’s shares have gained 12.02% in the last month. The stock is trading 3.78% above its 50-day moving average. Moreover, shares of the Company, which operates as an integrated pharmaceutical company worldwide, have an RSI of 51.04.

On June 19th, 2018, Dr. Reddy’s Labs announced that it has launched Levetiracetam in Sodium Chloride Injection, 500 mg/100 mL (5 mg/mL), 1,000 mg/100 mL (10 mg/mL), and 1,500 mg/100 mL (15 mg/mL) single-dose infusion bags, a therapeutic equivalent generic version of HQ Specialty Pharma Corporation’s Levetiracetam in Sodium Chloride Injection, approved by the U.S. Food and Drug Administration. Gain free access to the research report on RDY at:

www.wallstequities.com/registration/?symbol=RDY

MEI Pharma

San Diego, California-based MEI Pharma Inc.’s stock ended yesterday’s session 4.93% lower at $4.05 with a total trading volume of 228,120 shares. The Company’s shares have surged 28.57% in the past month, 96.60% over the previous three months, and 73.08% over the past year. The stock is trading 24.77% and 60.06% above its 50-day and 200-day moving averages, respectively. Additionally, shares of MEI Pharma, which focuses on the clinical development of drugs for the treatment of cancer, have an RSI of 52.38.

On June 04th, 2018, MEI Pharma announced that data presented at ASCO 2018 from a Phase-1b study of ME-401 demonstrate a 90% objective response rate in patients with relapsed or refractory follicular lymphoma, chronic lymphocytic lymphoma, and small lymphocytic lymphoma. Based on the data in this program, the Company anticipates progressing into a single-agent registration study later in 2018 for the treatment of adults with relapsed or refractory follicular lymphoma.Signing up today on Wall St. Equities will give you access to the latest report on MEIP at:

www.wallstequities.com/registration/?symbol=MEIP

Synergy Pharmaceuticals

On Wednesday, shares in New York headquartered Synergy Pharmaceuticals Inc. recorded a trading volume of 4.78 million shares, which was above their three months average volume of 3.60 million shares. The stock finished 8.47% lower at $1.62. The Company’s shares are trading below their 50-day moving average by 5.06%. Furthermore, shares of Synergy Pharma, which focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders, have an RSI of 41.94.

On June 13th, 2018, Synergy Pharmaceuticals (SGYP) announced that it has received a waiver to extend the draw down date of the second borrowing under its Term Loan Agreement with CRG L.P. from June 30th, 2018, to August 29th, 2018. SGYP has the ability to access up to $100 million in 2018 in three tranches under the amended Term Loan Agreement. Register now for today’s free coverage on SGYP at:

www.wallstequities.com/registration/?symbol=SGYP

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 503957